The tweet was deleted by the author.
But we saved everything 🙂.
Monte Rosa Therapeutics has been recognized as a Disruptive Pioneer by IDEA Pharma in the 2026 Innovation and Invention Index, an annual assessment honoring companies driving groundbreaking advances in healthcare.
The award spotlights Monte Rosa Therapeutics for its work on MGDs, which target historically undruggable proteins, potentially opening new therapeutic pathways. The company extended thanks to media outlets and journalists covering the achievement, including Stat News, Adam DeAngelis, and Matthew Herper.
View post on X Loading...
Earlier this year, Monte Rosa Therapeutics announced plans to detail new research on molecular glue degraders and cereblon at an Endpoints webinar on May 12. The company has focused on developing MGDs that address proteins previously considered difficult to target. These efforts have contributed to its recent industry recognition.